Evidence map›Paper›PMID 32989495›Full record

ArticleAnnals of hematology2020

Long-term follow-up of abbreviated R-CHOP chemoimmunotherapy for completely resected limited-stage diffuse large B cell lymphoma (CISL 12-09).

Sora Kang, Hyungwoo Cho, Byeong Seok Sohn, Sung Yong Oh, Won-Sik Lee, Sang Min Lee, Deok-Hwan Yang, Jooryung Huh, Dok Hyun Yoon, Cheolwon Suh

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01279902 (Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01279902 phase2unknown statusnot on this map

Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised Stage I or II CD20+ Diffuse Large B-cell Lymphoma

TypeinterventionalSponsorAsan Medical CenterRan2010 to 2017Enrolled32ConditionsDiffuse Large B-cell LymphomaArmsRituximab plus CHOP Immunochemotherapy
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Sora KangDepartment of Internal Medicine, Asan Medical Center, Seoul, South Korea.
Hyungwoo ChoDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Byeong Seok SohnDepartment of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, South Korea.
Sung Yong OhDepartment of Internal Medicine, Dong-A University Hospital, Busan, South Korea.
Won-Sik LeeDepartment of Hemato-Oncology, Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.
Sang Min LeeDepartment of Hemato-Oncology, Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea.
Deok-Hwan YangDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, South Korea.
Jooryung HuhDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. dhyoon@amc.seoul.kr.
Cheolwon SuhDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea. csuh@amc.seoul.kr.
Asan Medical Center · KRInje University Busan Paik Hospital · KRUniversity of Ulsan · KRChonnam National University Hwasun Hospital · KRDong-A University Hospital · KRInje University Sanggye Paik Hospital · KRUlsan College · KR

Funding

Asan Institute for Life Sciences, Asan Medical Center 2017-198
6 · The paper itself

Abstract

The standard of treatment for completely resected limited-stage diffuse large B cell lymphoma (DLBCL) in patients without residual lesions has not yet been established. Previously, we designed a phase II trial to evaluate the safety and efficacy of three cycles of abbreviated R-CHOP in patients with completely resected limited-stage DLBCL and reported favorable survival outcomes. We present the long-term follow-up results to taking into account the importance of delayed relapse in patients with limited-stage DLBCL. With a median follow-up duration of 62.7 months (range, 60.2-75.5 months), the 5-year OS and DFS rates were both 95.0% (95% confidence interval, 85.59-104.11%). Only one patient experienced disease progression which was confirmed at 12.3 months, and one patient with primary intestinal DLBCL developed non-small cell lung cancer 6 years after treatment. The long-term results of our data support the use of three cycles of abbreviated R-CHOP for patients with completely resected limited-stage DLBCL. The study was reviewed and approved by the review boards of the participating institutes and registered at ClinicalTrials.gov , number NCT01279902, in August 3, 2010.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinFemaleFollow-Up StudiesHumansImmunotherapyLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm StagingPrednisoneProspective StudiesRituximabCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineComplete resectionDiffuse large B cell lymphomaLimited stageR-CHOP

Identifiers

PMID32989495
OpenAlexW3089478563

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.